dotMD.com
✓ Translated by DotMD AI Clinical Council Source: JNCI cancer spectrum • Meta-Analysis
Verify Primary Source: NIH PubMed PMID #38781520
Plain-English Research Story • 8th-Grade Reading Level

New Insights on Interventions for trouble sleeping in cancer patients and survivors-a: What a 6,528-Participant Study Found

CBT-I is supported as a first-line treatment for trouble sleeping in cancer survivors, with significant benefits observed across sleep and non-sleep outcomes.

Original Paper Title: “Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis” (JNCI cancer spectrum, 2024-04-30)

Elena Rostova (AI Quant) Rigor Score
94 / 100
Sample Size (Participants)
N = 6,528
Evidence Classification
Meta-Analysis
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: CBT-I is supported as a first-line treatment for trouble sleeping in cancer survivors, with significant benefits observed across sleep and non-sleep outcomes.
  • Who Was Studied: Meta-Analysis published in JNCI cancer spectrum following 6,528 real-world participants.
  • Strength of the Evidence: Earned a 94/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

Considering the persistent nature and higher prevalence of trouble sleeping in cancer patients and survivors compared with the general population, there is a need for effective management strategies. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in JNCI cancer spectrum conducted a meta-analysis evaluating 6,528 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

CBT-I is supported as a first-line treatment for trouble sleeping in cancer survivors, with significant benefits observed across sleep and non-sleep outcomes. The findings also highlight the potential of less intensive alternatives. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in JNCI cancer spectrum (2024-04-30) • Study Design: Meta-Analysis • Participants: N = 6,528 • Biostatistical Rigor Score: 94/100. Primary Takeaway: CBT-I is supported as a first-line treatment for trouble sleeping in cancer survivors, with significant benefits observed across sleep and non-sleep outcomes.

Study Limitations & Caveats Before You Act

While this meta-analysis scored 94/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis”
Published in JNCI cancer spectrum (2024-04-30) • PMID/ID: 38781520
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38781520: New Insights on Interventions for trouble sleeping in cancer patients and survivors-a: What a 6,528-Participant Study Found

3 of 3 Free Questions Remaining